Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- ESMO open
- Publicado em
- 11 jul 2023
- Citações
- 14
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K Heinrich, M Karthaus, S Fruehauf, U Graeven, L Mueller, A O König, L Fischer von Weikersthal, K Caca, A Kretzschmar, E Goekkurt et al.
Descritores MeSH
- Colorectal Neoplasms
- Colonic Neoplasms
- Leucovorin
- Female
- Fluorouracil
- Humans
- Male
- Panitumumab
- Treatment Outcome
- Antineoplastic Combined Chemotherapy Protocols
Veja também
Estudos relacionados
- Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
- Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
- Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
- Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
- Resultados de Sobrevivência a Longo Prazo de FOLFOXIRI Modified-Plus Cetuximab versus Bevacizumab em Câncer Colorectal de Tipo Selvagem RAS/BRAF: Análise Final do Ensaio DEEPER